

Finance Committee

Committee Composition

Chair:	Treasurer of the European Society of Endocrinology.
Full members:	ESE President. ESE President-Elect. ESE Immediate past President*. ESE Immediate past Treasurer*. Up to two additional members proposed by the Committee outside of and ratified by the Executive Committee. A non-endocrinologist with a finance background should be considered. *If the immediate past President or Treasurer are not able to join then an alternative past President or Treasurer, current or previous ExCo member can be considered.
Ex-officio members:	Chief Executive Officer. Director of Strategic Partnerships.
Co-opted members:	Up to two additional members may be co-opted for a limited period to fulfil a specific role, subject to Executive Committee approval.

Quorum Fifty percent (50%) of Full Members (including the Chair) +1

Duration of Service

Chair(s):	Co-terminous with office.
Full members:	Four years or co-terminous with office, where applicable.
Ex-officio members:	Co-terminous with office.
Co-opted members:	Up to two years, but with the option to extend to four years in total with approval from the Executive Committee.

Reporting The Committee reports to the ESE Executive Committee through the Finance Committee Chair.

Meetings Two or three meetings per year (usually Spring, ECE (European Congress of Endocrinology) and Autumn). Usually held remotely by video conference.

Remit

The work of the Executive Committee is to report on the Society's strategy with the overall aim of attending to the sustainability of ESE and to participate in committee related email communications and review overall annual budgets, highlighting issues and make recommendations to the Executive Committee.

Committee members who do not attend three consecutive meetings (or one meeting in a year if meetings are held annually) will be asked to step down, other than in exceptional circumstances.

4. To review new projects and programs, and expansions to existing programs, which have a financial impact and make recommendations to the Executive Committee.

5. To review, usually via the Treasurer, the annual financial statements, before submission for approval by the Executive Committee.

6. To review the reserves policy.

7. To review the remuneration and bonus structure of the CEO

- All Committee members (except the non-endocrinologist) need to be paid up members of the European Society of Endocrinology.

- The work of the committee is very important. Committee members are expected to attend all committee meetings and to participate in committee related email communications.

- Committee members who do not attend three consecutive meetings (or one meeting in a year if meetings are held annually) will be asked to step down, other than in exceptional circumstances.

- The Committee will liaise with other ESE Committees as appropriate.

- All papers and minutes must be treated in strictest confidence.

- The use of an AI 'otter' to join meetings/take notes at a committee meeting is not permitted unless expressly authorised by the Chair.

- All Committee members must act in the best interest of the Society.

- Any potential conflicts of interest should be declared at the start of the meeting or as they arise, and the members concerned should take no part in the discussion.

- The Chair should not serve a second consecutive term of office, unless there are exceptional circumstances identified by the Executive Committee.

- The Society is committed to equal opportunities and the promotion of equality, diversity and inclusion and where possible this committee should follow the principles of [ESE's Equality, Diversity and Inclusion Policy](#).

- Committee membership should represent the key areas of interest; geographical spread; and gender considerations.

Additional notes

Current membership

Chair

Sebastian Neggers, Netherlands, co-terminous with office, (Treasurer, 2023- 2027)*

Full members

Wiebke Arlt, UK, co-terminous with office, (President, 2025-2027).

Jérôme Bertherat, France, co-terminous with office, (Past-President, 2025-2027).

Mirjam Christ-Crain, UK, co-terminous with office, (President-Elect, 2025-2027).

Bulent Yildiz, Turkey, co-terminous with office, (Previous Treasurer, 2025-2027).

Philip Cheek, UK, non-endocrinologist member.

Ex-officio

Helen Gregson, Chief Executive Officer, co-terminous with office.

Dirk De Rijdt, Director of Strategic Partnerships, co-terminous with office.

ESE Team member responsibility: Head of Governance, Finance and Office.